Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.

The asset-backed primary is bracing for another busy week after 16 issuers priced more than US$14.8bn last week, while the RMBS sector is expecting a number of jumbo deals. Over in the ECM, primary ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

Hata has grant/research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech, and Scorpion Therapeutics; ...

Overall, 49 patients (20 patients in Z1G and 29 in Z1H) were included in the primary efficacy analyses. The objective response rates in both cohorts were 0% (Z1G; 90% CI, 0 to 13.9) and 3.4% (Z1H; 90% ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...